Gregg Gonsalves, PhD
Associate Professor of Epidemiology (Microbial Diseases)Cards
Additional Titles
Associate (Adjunct) Professor of Law, Yale Law School
Affiliated Faculty, Program in Addiction Medicine
Co-Director, Global Health Justice Partnership
Affiliated Faculty, Yale Institute for Global Health
Contact Info
About
Titles
Associate Professor of Epidemiology (Microbial Diseases)
Associate (Adjunct) Professor of Law, Yale Law School; Affiliated Faculty, Program in Addiction Medicine; Co-Director, Global Health Justice Partnership; Affiliated Faculty, Yale Institute for Global Health
Biography
Gregg Gonsalves is an expert in policy modeling on infectious disease and substance use, as well as the intersection of public policy and health equity. His research focuses on the use of quantitative models for improving the response to epidemic diseases. For more than 30 years, he worked on HIV/AIDS and other global health issues with several organizations, including the AIDS Coalition to Unleash Power, the Treatment Action Group, Gay Men’s Health Crisis, and the AIDS and Rights Alliance for Southern Africa. He is a 2011 graduate of Yale College and received his PhD from Yale Graduate School of Arts and Sciences/School of Public Health in 2017. He is currently the public health correspondent for The Nation. He is a 2018 MacArthur Fellow.
Appointments
Epidemiology of Microbial Diseases
Associate Professor on TermPrimary
Other Departments & Organizations
Education & Training
- PhD
- Yale University, Public Health (2017)
- BS
- Yale College, Ecology and Evolutionary Biology (2011)
Research
Overview
Medical Subject Headings (MeSH)
ORCID
0000-0002-5789-9841
Research at a Glance
Yale Co-Authors
Publications Timeline
Research Interests
A. David Paltiel, MBA, PhD
Alexandra Savinkina, MSPH
Joseph Ross, MD, MHS
Thomas Thornhill IV
Haidong Lu, PhD
Danya Keene, PhD
Public Policy
United States Food and Drug Administration
Computer Simulation
Decision Making
Hepatitis C
Prisoners
Publications
Featured Publications
Estimating deaths averted and cost per life saved by scaling up mRNA COVID-19 vaccination in low-income and lower-middle-income countries in the COVID-19 Omicron variant era: a modelling study
Savinkina A, Bilinski A, Fitzpatrick M, Paltiel AD, Rizvi Z, Salomon J, Thornhill T, Gonsalves G. Estimating deaths averted and cost per life saved by scaling up mRNA COVID-19 vaccination in low-income and lower-middle-income countries in the COVID-19 Omicron variant era: a modelling study. BMJ Open 2022, 12: e061752. PMID: 36100306, PMCID: PMC9471205, DOI: 10.1136/bmjopen-2022-061752.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsLow-income countriesIncome countriesDeath avertedHigh-income nationsStatistical lifeAvertable deathsIncome nationsCOVID-19 deathsReasonable investmentHigh costKey inputCountriesParameter estimatesAvertedCostSensitivity analysisUniversal vaccinationGlobal vaccinationMRNA COVID-19 vaccinationNationsInvestmentPrimary vaccine seriesLow vaccine effectivenessCOVID-19 vaccinationPublic dataSurveillance for endemic infectious disease outbreaks: Adaptive sampling using profile likelihood estimation
Fairley M, Rao IJ, Brandeau ML, Qian GL, Gonsalves GS. Surveillance for endemic infectious disease outbreaks: Adaptive sampling using profile likelihood estimation. Statistics In Medicine 2022, 41: 3336-3348. PMID: 35527474, PMCID: PMC9283243, DOI: 10.1002/sim.9420.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and Concepts
2024
The Evolution of Selection Bias in the Recent Epidemiologic Literature—A Selective Overview
Lu H, Howe C, Zivich P, Gonsalves G, Westreich D. The Evolution of Selection Bias in the Recent Epidemiologic Literature—A Selective Overview. American Journal Of Epidemiology 2024, kwae282. PMID: 39136207, DOI: 10.1093/aje/kwae282.Peer-Reviewed Original ResearchAltmetricDéjà Vu All Over Again — Refusing to Learn the Lessons of Covid-19
Sinha M, Parmet W, Gonsalves G. Déjà Vu All Over Again — Refusing to Learn the Lessons of Covid-19. New England Journal Of Medicine 2024, 391: 481-483. PMID: 39047237, DOI: 10.1056/nejmp2406427.Peer-Reviewed Original ResearchAltmetricProjecting the Potential Clinical and Economic Impact of Human Immunodeficiency Virus Prevention Resource Reallocation in Tennessee
Borre E, Ahonkhai A, Chi K, Osman A, Thayer K, Person A, Weddle A, Flanagan C, Pettit A, Closs D, Cotton M, Agwu A, Cespedes M, Ciaranello A, Gonsalves G, Hyle E, Paltiel A, Freedberg K, Neilan A. Projecting the Potential Clinical and Economic Impact of Human Immunodeficiency Virus Prevention Resource Reallocation in Tennessee. Clinical Infectious Diseases 2024, ciae243. PMID: 38913762, DOI: 10.1093/cid/ciae243.Peer-Reviewed Original ResearchAltmetricConceptsCenters for Disease Control and PreventionIncrease HIV testingHuman immunodeficiency virus testingHuman immunodeficiency virusPriority populationsPrEP provisionCare linkageHIV testingPrevention fundingSurvivors of sex traffickingPregnant peopleTransgender womenLife yearsCondom useHIV prevention fundsUS Centers for Disease Control and PreventionDisease Control and PreventionBaseline condom useControl and PreventionReduced condom useHuman immunodeficiency virus transmissionHeterosexual Black womenPreexposure prophylaxisHIV transmissionBlack womenThe surge of mpox in Africa: a call for action
Nachega J, Sam-Agudu N, Ogoina D, Mbala-Kingebeni P, Ntoumi F, Nakouné E, Njouom R, Lewis R, Gandhi M, Rosenthal P, Rawat A, Wilson L, Kindrachuk J, Liesenborghs L, Mills E, Preiser W, Rimoin A, Sullivan N, Peeters M, Delaporte E, Baxter C, Harrison L, Hermans M, Mohr E, Gonsalves G, Ndembi N, Zumla A, Muyembe-Tamfum J, Consortium M. The surge of mpox in Africa: a call for action. The Lancet Global Health 2024, 12: e1086-e1088. PMID: 38735300, DOI: 10.1016/s2214-109x(24)00187-6.Peer-Reviewed Original ResearchCitationsAltmetricComparing frequency of booster vaccination to prevent severe COVID-19 by risk group in the United States
Park H, Gonsalves G, Tan S, Kelly J, Rutherford G, Wachter R, Schechter R, Paltiel A, Lo N. Comparing frequency of booster vaccination to prevent severe COVID-19 by risk group in the United States. Nature Communications 2024, 15: 1883. PMID: 38448400, PMCID: PMC10917753, DOI: 10.1038/s41467-024-45549-9.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsSevere COVID-19Risk of severe COVID-19COVID-19 booster vaccinationBooster vaccinationHigh-risk populationAbsolute annual riskWaning of protectionImmunocompromised populationsFrequent boostingOlder age groupsAnnual boosterImmune evasionImmunocompromised personsPublic health needsPublic health guidanceRisk groupsFrequent boostersImmune statusRisk factorsFrequency of booster vaccinationHealth needsHealth guidanceCompare frequenciesAge groupsVaccineAccessibility of Opioid Treatment Programs Based on Conventional vs Perceived Travel Time Measures
Kim J, Lee J, Thornhill T, Dennett J, Lu H, Howell B, Grau L, Fiellin D, Heimer R, Gonsalves G. Accessibility of Opioid Treatment Programs Based on Conventional vs Perceived Travel Time Measures. JAMA Network Open 2024, 7: e240209. PMID: 38376839, PMCID: PMC10879949, DOI: 10.1001/jamanetworkopen.2024.0209.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsTransit travel timeAccessibility metricsTravel timeTravel componentsAccessibility scoresTransportation burdenTravel burdenOut-of-vehicleComponents of travelConventional accessibility measuresSpatial regression modelsTravel time measurementsPublic transitTransit schedulesAccessibility measuresDeparture timeTravel time analysisTrip durationTravelOperating hoursTime analysisCross-sectional studyOpioid use disorderPolicy recommendationsDecision-making
2023
Clade I–Associated Mpox Cases Associated with Sexual Contact, the Democratic Republic of the Congo - Volume 30, Number 1—January 2024 - Emerging Infectious Diseases journal - CDC
Kibungu E, Vakaniaki E, Kinganda-Lusamaki E, Kalonji-Mukendi T, Pukuta E, Hoff N, Bogoch I, Cevik M, Gonsalves G, Hensley L, Low N, Shaw S, Schillberg E, Hunter M, Lunyanga L, Linsuke S, Madinga J, Peeters M, Cigolo J, Ahuka-Mundeke S, Muyembe J, Rimoin A, Kindrachuk J, Mbala-Kingebeni P, Lushima R, Consortium I. Clade I–Associated Mpox Cases Associated with Sexual Contact, the Democratic Republic of the Congo - Volume 30, Number 1—January 2024 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2023, 30: 172-176. PMID: 38019211, PMCID: PMC10756366, DOI: 10.3201/eid3001.231164.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and Concepts965. Projecting the Potential Clinical and Economic Impact of HIV Prevention Resource Reallocation in Tennessee
Borre E, Ahonkhai A, Chi K, Osman A, Thayer K, Person A, Weddle A, Flanagan C, Pettit A, Closs D, Cotton M, Agwu A, Cespedes M, Ciaranello A, Gonsalves G, Hyle E, Paltiel A, Freedberg K, Neilan A. 965. Projecting the Potential Clinical and Economic Impact of HIV Prevention Resource Reallocation in Tennessee. Open Forum Infectious Diseases 2023, 10: ofad500.2460. PMCID: PMC10678140, DOI: 10.1093/ofid/ofad500.2460.Peer-Reviewed Original ResearchCitationsConceptsHIV testingHIV prevention fundingHIV transmissionDeath avertedTransgender womenPregnant peopleHIV careRisk groupsCondom usePrevention fundingHIV testing ratesPre-exposure prophylaxisHIV testing frequencyPriority risk groupBlack womenHeterosexual Black womenNumber of peoplePrEP provisionVirologic suppressionIncident HIVUndiagnosed HIVHIV deathsPrEP usePotential ClinicalClinical impact
Academic Achievements & Community Involvement
honor MacArthur Fellowship
National AwardJohn D. and Catherine T. MacArthur FoundationDetails10/04/2018United States
News & Links
News
- August 30, 2024Source: The Guardian
U.S. repeating Covid mistakes with bird flu as spread raises alarm, experts say
- August 28, 2024Source: WNPR
Anti-vaccine rhetoric has hit the campaign trail
- August 14, 2024Source: New York Times
W.H.O. Declares Global Emergency Over New Mpox Outbreak
- July 24, 2024Source: The New England Journal of Medicine
Déjà Vu All Over Again — Refusing to Learn the Lessons of Covid-19
Get In Touch
Contacts
Locations
Public Health Modeling Unit
Academic Office
350 George Street, Ste 3rd Floor
New Haven, CT 06511